Lentivirus Biodistribution

The Lentivirus Biodistribution (RNA ISH assay) Services from Creative Bioarray provide an unparalleled sensitive and specific method for cell and tissue-specific assessment of gene therapy lentiviral vector and transgene expression analysis in any tissue.

RNA in situ hybridization (ISH) has emerged as a significant technique in deciphering the biodistribution of lentivirus in gene therapy efforts. This method employs complementary strands of RNA probes to detect distinct genes, theoretically pin-pointing their exact location within the tissue. The application of RNA ISH in lentivirus biodistribution studies in gene therapy revolves around the in-depth visualization of viral vectors' distribution within tissues. An RNA probe is synthetized to correspond a sequence in the lentivirus vector, and once the probe hybrids with the target RNA in the tissue, researchers can visualize the exact location of the viral vector.

One of the significant technical advantages of RNA ISH over other methods is its high sensitivity and precision. Unlike PCR which may provide quantitative data but lacks spatial information, RNA ISH can reveal the exact localization of lentivirus vectors inside specific cells or tissues.

Another advantage is its ability to detect and visualize both abundant and rare messages within the complex tissue environment, a feature that is rarely achieved by other molecular techniques. For instance, RNA ISH can reveal the lentiviral vector position in a single neuron within complex neural tissue.

Moreover, RNA ISH provides researchers with the ability to monitor the active expression of viral vector payload. This is critical in gene therapy as it offers an extra layer of information by allowing examination of the functional success of the gene transfer besides just the spatial localization of the vector.

Lastly, RNA ISH can be utilized in formalin-fixed, paraffin-embedded (FFPE) tissues samples, making it a useful tool in retrospective studies where only FFPE samples might be accessible. So, due to its high sensitivity, exact localization, and overall versatility, RNA ISH method provides a powerful tool in studying lentivirus biodistribution in gene therapy.

Recent commercialization of lentiviral vector (LV)-based cell therapies and successful reports of clinical studies have demonstrated the untapped potential of LVs to treat diseases and benefit patients. LVs hold notable and inherent advantages over other gene transfer agents based on their ability to transduce non-dividing cells, permanently transform target cell genome, and allow stable, long-term transgene expression. An important aspect of characterizing new gene therapy vectors is their tissue biodistribution.

Lentivirus Biodistribution Tests Available:

Quotation and ordering

Our customer service representatives are available 24hr a day! We thank you for choosing Creative Bioarray as your preferred Lentivirus Biodistribution Service provider.

References

1. Food and Drug Administration, 1991, Points to consider in human somatic cell therapy and gene therapy
2. Bosse, Roland, et al. "Good manufacturing practice production of human stem cells for somatic cell and gene therapy." Stem cells 15.S2 (1997): 275-280.
3. Pilaro, Anne M., and Mercedes A. Serabian. "Preclinical development strategies for novel gene therapeutic products." Toxicologic pathology 27.1 (1999): 4-7.
4. Verdier, F., and J. Descotes. "Preclinical safety evaluation of human gene therapy products." Toxicological sciences: an official journal of the Society of Toxicology 47.1 (1999): 9-15.
5. Podsakoff, Greg M. "Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector." Molecular Therapy 4.4 (2001): 282-283.
6. Naldini, Luigi, et al. "In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector." Science 272.5259 (1996): 263-267.
7. Romano, Gaetano, et al. "Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications." Stem cells 18.1 (2000): 19-39.
8. Pan, Dao, et al. "Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow." Molecular Therapy 6.1 (2002): 19-29.